PKS Advisory Services’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$334K Buy
5,504
+24
+0.4% +$1.4K 0.08% 195
2025
Q4
$296K Sell
5,480
-41
-0.7% -$1.97K 0.07% 200
2025
Q3
$249K Buy
5,521
+103
+2% +$4.81K 0.05% 216
2025
Q2
$251K Sell
5,418
-339
-6% -$16.6K 0.06% 228
2025
Q1
$349K Buy
5,757
+384
+7% +$22.4K 0.1% 165
2024
Q4
$304K Buy
+5,373
New +$300K 0.08% 187

Other funds holding BMY

PKS Advisory Services's BMY Position: Q1 2026 in Review

PKS Advisory Services increased its Bristol-Myers Squibb (BMY) stake by 0.44% in Q1 2026, buying an estimated $1.4K and bringing the position to 5,504 shares worth $334K. The position accounts for 0.08% of the portfolio, ranked #195.

PKS Advisory Services first reported a position in BMY in Q4 2024 and has held it in 6 quarters since. The position peaked at $349K in Q1 2025. 2,517 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • PKS Advisory Services held 5,504 shares of Bristol-Myers Squibb worth $334K as of Q1 2026.
  • PKS Advisory Services bought 24 Bristol-Myers Squibb shares in Q1 2026, an estimated $1.4K.
  • Bristol-Myers Squibb made up 0.08% of PKS Advisory Services's portfolio in Q1 2026, its #195 holding.
  • PKS Advisory Services first reported a position in Bristol-Myers Squibb in Q4 2024 and has held it in 6 quarters since.
  • PKS Advisory Services's Bristol-Myers Squibb position peaked at $349K in Q1 2025.
  • 2,517 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on PKS Advisory Services's 13F filing for Q1 2026, filed 13 May 2026.